EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics

Michael P Ayers, Christopher M Kramer iD

Circulation · 2023

DOI: 10.1161/circulationaha.123.065789 ↗

Kurz gefasst

Editorial in der Zeitschrift Circulation, 2023. Verfasst von Michael P Ayers und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the Cardiovascular Division, Department of Medicine (M.P.A., C.M.K.), University of Virginia Health System, Charlottesville. Hauptthemen laut MEDLINE: Sarcomeres, Cardiomyopathy, Hypertrophic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ypertrophic cardiomyopathy (HCM) is a heterogeneous disease unified under the broad umbrella of increased left ventricular (LV) thickness in the absence of another cause. 1 Long before the unravelling of the genetic underpinnings, first as a monogenic disorder of the sarcomere 2 and more recently in sarcomere mutation-negative patients as a polygenic predisposition with environmental triggers such as hypertension, 3 the histological hallmark of HCM has been myofibrillar disarray.As the microscopic disorder progresses, so do varying degrees of microvascular dysfunction, fibrosis, both replacement and interstitial, myocyte hypertrophy, and LVH. 4 The exact interrelations among these factors, however, are nonlinear and challenging to tease apart.4 In the end, what is left behind is both substrate and trigger for arrhythmias and heart failure.Predicting risk of sudden cardiac death is the goal of recently updated European Society of Cardiology guidelines 5 (a quantitative score) and American Heart Association/American College of Cardiology guidelines 1 (more qualitative).None of the currently used risk models are aimed at predicting the risk of heart failure or other causes of mortality in HCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomeresCardiomyopathy, HypertrophicHumansBiomarkersPhenotypeMutation

Stichwörter der Autor:innen

Editorialscardiomyopathy, hypertrophic

Substanzen

Biomarkers

Autor:innen und Institutionen

  • From the Cardiovascular Division, Department of Medicine (M.P.A., C.M.K.), University of Virginia Health System, Charlottesville.
  • Department of Radiology and Medical Imaging (C.M.K.), University of Virginia Health System, Charlottesville.

ORCID-Profile: Christopher M Kramer

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ayers, M. P., & Kramer, C. M. (2023). Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics. Circulation. https://doi.org/10.1161/circulationaha.123.065789

Vancouver

Ayers MP, Kramer CM. Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics. Circulation. 2023. doi:10.1161/circulationaha.123.065789

BibTeX
@article{Ayers2023,
  author = {Ayers, Michael P and Kramer, Christopher M},
  title = {Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics},
  journal = {Circulation},
  year = {2023},
  doi = {10.1161/circulationaha.123.065789}
}
Kostenlos starten →